{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["334(11)"],"submitter":["DIAMOND Study Group"],"pubmed_abstract":["<h4>Importance</h4>With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival.<h4>Objective</h4>To evaluate the efficacy and safety of toripalimab incorporated into induction chemotherapy and radiotherapy, without concurrent cisplatin, for locoregionally advanced NPC.<h4>Design, setting, and participants</h4>Open-label, multicenter, randomized phase 3 clinical trial conducted from August 2021 to July 2022 at 13 hospitals in China, enrolling 532 patients with T4N1M0 or T1-4N2-3M0 NPC; 400 (75.2%) completed the trial per protocol. The final date of follow-up was March 21, 2025.<h4>Interventions</h4>Patients were randomly assigned to either the standard therap"],"journal":["JAMA"],"pagination":["973-983"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12371549"],"repository":["biostudies-literature"],"pubmed_title":["Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial."],"pmcid":["PMC12371549"],"pubmed_authors":["She LJ","Tang XH","Huang J","Lu LX","Zhang N","Huang L","Guo R","Wang XH","Chen XZ","Jin F","Guo L","Tang LL","Qiang MY","Zang SB","Liu LZ","Wang Y","Su Y","Lin AH","Liu LT","Wu Y","Ouyang PY","Shen LF","Liu WX","Li YQ","Huang HL","Chen L","Hong SB","Jie YS","Xu C","Zeng WH","Zou GR","Li L","Sun Y","Ye ZL","Du XJ","Li HJ","Yang Q","Huang XQ","Lin L","Wei HM","Yang KY","Li JB","Zhu XD","Liu N","Zhao HY","Hu DS","Liu X","Li YY","Xie FY","DIAMOND Study Group","Zeng YC","Tian L","Lv JW","Hu GY","Zhou GQ","Peng YL","Li WF","Liang XY","Du ZM","Chen YP","Mao YP","Huang Y","Long GX","Xiang YQ","Yun JP","Zhang Y","Ma J","Liang YL","Xiao SW","Li JG","Han F"],"additional_accession":[]},"is_claimable":false,"name":"Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.","description":"<h4>Importance</h4>With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival.<h4>Objective</h4>To evaluate the efficacy and safety of toripalimab incorporated into induction chemotherapy and radiotherapy, without concurrent cisplatin, for locoregionally advanced NPC.<h4>Design, setting, and participants</h4>Open-label, multicenter, randomized phase 3 clinical trial conducted from August 2021 to July 2022 at 13 hospitals in China, enrolling 532 patients with T4N1M0 or T1-4N2-3M0 NPC; 400 (75.2%) completed the trial per protocol. The final date of follow-up was March 21, 2025.<h4>Interventions</h4>Patients were randomly assigned to either the standard therap","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-16T13:02:06.957Z","creation":"2026-07-09T10:56:34.852Z"},"accession":"S-EPMC12371549","cross_references":{"pubmed":["40839372"],"doi":["10.1001/jama.2025.13205"]}}